| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas
|
Suh, Young Joo
|
|
2018
|
120 |
C |
p. 130-136
|
artikel
|
| 2 |
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
|
Reck, Martin
|
|
2018
|
120 |
C |
p. 62-69
|
artikel
|
| 3 |
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
|
Forster, Martin
|
|
2018
|
120 |
C |
p. 27-33
|
artikel
|
| 4 |
Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy
|
Lee, Chia Ching
|
|
2018
|
120 |
C |
p. 54-59
|
artikel
|
| 5 |
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
|
Bradbury, Penelope A.
|
|
2018
|
120 |
C |
p. 142-148
|
artikel
|
| 6 |
Contents
|
|
|
2018
|
120 |
C |
p. v-vi
|
artikel
|
| 7 |
Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand
|
Limwattananon, Chulaporn
|
|
2018
|
120 |
C |
p. 91-97
|
artikel
|
| 8 |
Editorial Board
|
|
|
2018
|
120 |
C |
p. iii
|
artikel
|
| 9 |
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism
|
Liu, Sangtian
|
|
2018
|
120 |
C |
p. 82-87
|
artikel
|
| 10 |
Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy
|
Yen, Chih-Chieh
|
|
2018
|
120 |
C |
p. 149-151
|
artikel
|
| 11 |
Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer
|
Kimura, Shinichi
|
|
2018
|
120 |
C |
p. 98-107
|
artikel
|
| 12 |
Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis
|
Verma, Vivek
|
|
2018
|
120 |
C |
p. 7-13
|
artikel
|
| 13 |
Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program
|
Reiter, Michael J.
|
|
2018
|
120 |
C |
p. 1-6
|
artikel
|
| 14 |
Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance
|
Du, Meijun
|
|
2018
|
120 |
C |
p. 113-121
|
artikel
|
| 15 |
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations
|
Ricciuti, Biagio
|
|
2018
|
120 |
C |
p. 70-74
|
artikel
|
| 16 |
Lorlatinib – Induced pulmonary arterial hypertension
|
Chabrol, Alexandre
|
|
2018
|
120 |
C |
p. 60-61
|
artikel
|
| 17 |
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma
|
Kopecka, Joanna
|
|
2018
|
120 |
C |
p. 34-45
|
artikel
|
| 18 |
Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis
|
Yang, Lin
|
|
2018
|
120 |
C |
p. 22-26
|
artikel
|
| 19 |
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
|
Guibert, Nicolas
|
|
2018
|
120 |
C |
p. 108-112
|
artikel
|
| 20 |
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
|
Maymani, Hossein
|
|
2018
|
120 |
C |
p. 137-141
|
artikel
|
| 21 |
Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer
|
Robin, Tyler P.
|
|
2018
|
120 |
C |
p. 88-90
|
artikel
|
| 22 |
Risk factors for pulmonary nodules in north China: A prospective cohort study
|
He, Yu-Tong
|
|
2018
|
120 |
C |
p. 122-129
|
artikel
|
| 23 |
The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)
|
Muley, Thomas
|
|
2018
|
120 |
C |
p. 46-53
|
artikel
|
| 24 |
Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III
|
Yanagawa, Naoki
|
|
2018
|
120 |
C |
p. 14-21
|
artikel
|
| 25 |
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden
|
Tendler, Salomon
|
|
2018
|
120 |
C |
p. 75-81
|
artikel
|
Tijdschrift beschrijving